Should We Use Glucocorticoid in Early Rheumatoid Arthritis? : Results at 5 Years from the ERA Louvain Brussels Cohort Emilie Sapart, MD – Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC)
5:10 PM – 5:20 PM ET
Treat-to Target for Early RA Patients in Usual Clinical Practice, a Randomized Study with a Favorable Effect of a Second Oral Pulse of Prednisolone. the Amsterdam COBRA Treat-to-target Study Linda Hartman, MSc – Amsterdam UMC, location VUmc
5:20 PM – 5:30 PM ET
Stable versus Tapered and Withdrawn Treatment with Tumor Necrosis Factor Inhibitor in Rheumatoid Arthritis Remission: A Randomized, Open-Label, Phase 4, Non-Inferiority Trial Siri Lillegraven, MD, PhD, MPH – Diakonhjemmet Hospital
5:30 PM – 5:40 PM ET
Olokizumab Improves Patient Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Results from the Double-Blind, Randomized Controlled Phase III Study Mariana Ivanova, MD, PhD – Clinic of Rheumatology, University Hospital "St. Ivan Rilski", Medical Faculty, Medical University, Sofia, Bulgaria
5:40 PM – 5:50 PM ET
A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to Methotrexate Maya H. H. Buch, MD, PhD – University of Manchester
